People

Dr Peter Jackson

- Chairman

Formerly Vice President of Avecia’s Pharmaceutical Products business and CEO of Reaxa Ltd which was sold to Johnson Matthey . Pete is also co-founder and Non-Executive Director of Redx Pharma and founder of ADC Biotechnology and has over twenty five years’ experience in the sector including the commercialisation of innovative technologies and forming, funding, development and exiting of technology start-ups. Pete provides YProTech with valuable strategic guidance and commercial support.


Dr Thomas Screen

- Operations Director

Tom worked for 6 years at catalyst technology company Reaxa as R&D manager developing applications and variants of the company’s encapsulated EnCatTM metal catalysts and new immobilisation technologies. He previously worked on FTE and custom synthesis projects at Peakdale Molecular and has a PhD and post-doctoral background in organic synthesis and catalytic reactions. An experienced project manager, including two RDA funded research projects and leading a current £1.4M multi-partner TSB supported project, and with nine years of technology and chemistry process development, Tom will provide project management and line management for the company’s operations.


Dr Stuart Brown

- Business Development & Marketing Director

Stuart previously worked for four years as an R&D Project Leader with Avecia, and prior to that worked for six years as a Chemistry Team Leader at SAFC Pharma (formerly Ultrafine Chemicals Ltd). In both roles he was responsible for the technical management and delivery of customer projects varying from lead optimisation programmes to process development and scale up manufacture (typically 1000L, GMP). During the last five years Stuart was employed as a Knowledge Transfer Manager with the Knowledge Centre for Materials Chemistry (KCMC) focussed on developing collaborative R&D projects between the KCMC partner institutions and Industry. With fifteen years experience in the Chemical Industry Stuart brings both technical experience and commercial knowledge to the company.


Dr Tony Flinn

- Non-Executive Director

Tony is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he helps assess service company (CRO) investment opportunities and works with the Fund’s smaller investments to help companies successfully grow. Tony is a well-known non-executive director and motivational speaker who co-founded Onyx Scientific in 2000 to offer contract chemistry services to many of the world’s leading drug developers. He grew the business to become one the fastest growing technology companies in the UK, employing more than 60 staff at its peak, managed an MBO in 2007, and ultimately sold the business to IPCA, a large Indian pharmaceutical service provider, in 2011. Tony began his career as a Post-Doctoral Research Fellow, first with the Cancer Research Institute, and then with Oxford University. After a period as a Research Chemist with Dow Chemical he began the first of several business development roles.


Acceleris Capital

- Financial Advisors

Acceleris Capital provides corporate finance advice and raises funds for early and development stage businesses and is authorised and regulated by the Financial Conduct Authority. As part of Seneca Partners, Acceleris are able to offer a wide range of funding solutions for SME’s.

Acceleris


Prof John Blacker

- Technical Consultant

Prof John Blacker was formerly R&D Director for Avecia Pharmaceuticals and has extensive industrial experience in catalyst technology and process R&D. His research includes the catalytic hydrogen transfer systems CATHy, SCRAM and CP-STAR. In 2009 he helped establish the Institute of Process Research and Development (iPRD) at the University of Leeds which has unique laboratory and small-scale production facilities. He has developed new process technologies and supported manufacture of a number of high-value fine chemicals and pharmaceuticals.


Research Team

YProtech has an experienced team of synthetic organic chemists available to execute our customer-driven chemistry projects. All our chemists are PhD-trained with collectively over 50 years industry experience.